In 2018, FDA approved tafenoquine (Arakoda) for malaria chemoprophylaxis in nonpregnant women and adults aged ≥18 years who are not G6PD deficient as confirmed by a quantitative G6PD test result (75). Here, G6PD is linked to malaria.